We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for DXC Technology's (DXC) Q1 Earnings?
Read MoreHide Full Article
DXC Technology Company (DXC - Free Report) is set to release first-quarter fiscal 2021 results on Aug 6.
The Zacks Consensus Estimate for quarterly revenues is pinned at $4.24 billion, calling for a 13.4% year-over-year decline. The consensus mark for earnings is 11 cents per share, suggesting a 93.7% slump.
The company’s earnings outpaced estimates in three of the trailing four quarters and missed in the other, the average beat being 9.3%.
Let’s see how things have shaped up for the upcoming announcement.
DXC’s fiscal first-quarter performance is likely to have been affected by the pandemic-induced business disruptions. Soft IT spending as organizations are pushing back their investments in big and expensive technology products, due to the global economic slowdown concerns amid the coronavirus crisis, might have hurt the company’s performance during the quarter to be reported.
Also, during the fourth-quarter fiscal 2020 earnings call, the company had stated that it anticipates revenue loss due to price concessions and terminated businesses to continue in first-quarter fiscal 2021. As a result, the company forecasts an 8-10% sequential decline in the fiscal first-quarter revenues.
Moreover, a weak traditional business is likely to have negatively impacted the top line during the quarter under review.
Furthermore, increased investments in the business and higher interest expenses are expected to have weighed on the company’s quarterly performance.
What Our Model Says
Our proven model does not predict an earnings beat for DXC this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
DXC carries a Zacks Rank of 4 (Sell) and has an Earnings ESP of 0.00%, at present.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combinations of elements to post an earnings beat this quarter:
Synaptics (SYNA - Free Report) has an Earnings ESP of +10.6 % and currently carries a Zacks Rank of 2.
Benefitfocus has an Earnings ESP of +6.25% and carries a Zacks Rank of 2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
What's in the Cards for DXC Technology's (DXC) Q1 Earnings?
DXC Technology Company (DXC - Free Report) is set to release first-quarter fiscal 2021 results on Aug 6.
The Zacks Consensus Estimate for quarterly revenues is pinned at $4.24 billion, calling for a 13.4% year-over-year decline. The consensus mark for earnings is 11 cents per share, suggesting a 93.7% slump.
The company’s earnings outpaced estimates in three of the trailing four quarters and missed in the other, the average beat being 9.3%.
Let’s see how things have shaped up for the upcoming announcement.
DXC Technology Company. Price and Consensus
DXC Technology Company. price-consensus-chart | DXC Technology Company. Quote
Factors at Play
DXC’s fiscal first-quarter performance is likely to have been affected by the pandemic-induced business disruptions. Soft IT spending as organizations are pushing back their investments in big and expensive technology products, due to the global economic slowdown concerns amid the coronavirus crisis, might have hurt the company’s performance during the quarter to be reported.
Also, during the fourth-quarter fiscal 2020 earnings call, the company had stated that it anticipates revenue loss due to price concessions and terminated businesses to continue in first-quarter fiscal 2021. As a result, the company forecasts an 8-10% sequential decline in the fiscal first-quarter revenues.
Moreover, a weak traditional business is likely to have negatively impacted the top line during the quarter under review.
Furthermore, increased investments in the business and higher interest expenses are expected to have weighed on the company’s quarterly performance.
What Our Model Says
Our proven model does not predict an earnings beat for DXC this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.
DXC carries a Zacks Rank of 4 (Sell) and has an Earnings ESP of 0.00%, at present.
Stocks With Favorable Combinations
Here are some companies, which, per our model, have the right combinations of elements to post an earnings beat this quarter:
Cogent Communications Holdings (CCOI - Free Report) has an Earnings ESP of +11.66% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Synaptics (SYNA - Free Report) has an Earnings ESP of +10.6 % and currently carries a Zacks Rank of 2.
Benefitfocus has an Earnings ESP of +6.25% and carries a Zacks Rank of 2, currently.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>